MedPacto Collaborates with Gangnam Severance and Soonchunhyang University Seoul Hospital on 'Cancer Diagnostic Kit' Joint Research
Measurement of BAG2 Protein Expression Levels in Blood
[Asia Economy Reporter Lee Gwan-joo] MedPacto announced on the 7th that it will conduct joint research on a cancer diagnostic kit capable of diagnosing cancer through blood with Gangnam Severance Hospital of Yonsei University and Soonchunhyang University Seoul Hospital.
The cancer diagnostic kit 'Mo-B2' based on the BAG2 biomarker, developed by MedPacto, diagnoses cancer by measuring the expression level of the BAG2 protein present in the blood.
Currently, cancer diagnosis has mainly been confirmed through tissue biopsy or imaging tests. The cancer diagnostic kit under research diagnoses cancer by the expression level of BAG2 secreted from tumor cells in the blood, and the company explained that it is expected to confirm the prognosis of cancer faster than existing cancer diagnostics.
The research, led by Professor Jeong Jun of Gangnam Severance Hospital, Yonsei University, and Professor Bang Hae-in of Soonchunhyang University Seoul Hospital, is conducted by comparing blood samples from breast cancer patients at Gangnam Severance Hospital and general blood samples from Soonchunhyang University Seoul Hospital.
A MedPacto official said, “This research aims to verify the potential of BAG2 as a cancer diagnostic biomarker by comparing the levels of BAG2 in plasma and serum in the blood of healthy individuals and cancer patients,” adding, “Since we are also developing an antibody therapeutic targeting BAG2 along with the cancer diagnostic kit under development, we expect companion diagnostic treatment to be possible for cancer patients in the future.”
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Introduces New "Special Performance Bonus" for Semiconductors, Paid Entirely in Company Shares
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Producer Price Index Hits Highest Growth in 28 Years... Consumer Price Pressure Mounts
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Meanwhile, MedPacto has signed a contract with the global medical device company Thermo Fisher Scientific for the development and production of diagnostic kits, and completed patent registration for the diagnostic kit in March last year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
